Receptor activator of NF-kB (rank) expression in primary tumors associates with bone metastasis occurrence in breast cancer patients

PLoS ONE

Volumn 6, Issue 4, 2011, Pages

  Santini, Daniele ^a   Schiavon, Gaia ^a,b   Vincenzi, Bruno ^a   Gaeta, Laura ^a   Pantano, Francesco ^a   Russo, Antonio ^c   Ortega, Cinzia ^d   Porta, Camillo ^e   Galluzzo, Sara ^a   Armento, Grazia ^a   La Verde, Nicla ^f   Caroti, Cinzia ^g   Treilleux, Isabelle ^h   Ruggiero, Alessandro ^b   Perrone, Giuseppe ^a   Addeo, Raffaele ⁱ   Clezardin, Philippe ^h   Muda, Andrea Onetti ^a   Tonini, Giuseppe ^a  

^a UNIVERSITY CAMPUS BIO MEDICO   (Italy)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c UNIVERSITY OF PALERMO   (Italy)

^d CANDIOLO CANCER INSTITUTE   (Italy)

^e FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^f FATEBENEFRATELLI HOSPITAL   (Italy)

^g GALLIERA HOSPITAL   (Italy)

^h UNIVERSITÉ LYON 1   (France)

ⁱ SAN GIOVANNI DI DIO HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MESSENGER RNA; OSTEOCLAST DIFFERENTIATION FACTOR; LIGAND; OSTEOPROTEGERIN; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; TNFRSF11A PROTEIN, HUMAN;

ADULT; ARTICLE; BONE METASTASIS; BREAST CANCER; CANCER PATIENT; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE FREE SURVIVAL; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MICROARRAY ANALYSIS; OVERALL SURVIVAL; PREDICTIVE VALUE; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; SURVIVAL RATE; AGED; BIOSYNTHESIS; BONE TUMOR; BREAST TUMOR; DNA MICROARRAY; FEMALE; GENE EXPRESSION REGULATION; METABOLISM; METASTASIS; METHODOLOGY; MIDDLE AGED; PATHOLOGY;

AGED; BONE NEOPLASMS; BREAST NEOPLASMS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; LIGANDS; MIDDLE AGED; NEOPLASM METASTASIS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; OSTEOPROTEGERIN; RANK LIGAND; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR-KAPPA B; RNA, MESSENGER;

EID: 79955772442     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0019234     Document Type: Article

References (40)

1. Boyce BF, Xing L, (2008) Functions of RANKL/RANK/OPG in bone modeling and remodeling. Arch Biochem Biophys 473: 139-146.
2. Kong YY, Yoshida H, Sarosi I, Tan HL, Timms E, et al. (1999) OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 397: 315-323.
3. Lacey DL, Tan HL, Lu J, Kaufman S, Van G, et al. (2000) Osteoprotegerin ligand modulates murine osteoclast survival in vitro and in vivo. Am J Pathol 157: 435-438.
4. Dougall WC, Glaccum M, Charrier K, Rohrbach K, Brasel K, et al. (1999) RANK is essential for osteoclast and lymph node development. Genes Dev 13: 2412-2424.
5. Li J, Sarosi I, Yan XQ, Morony S, Capparelli C, et al. (2000) RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism. Proc Natl Acad Sci USA 97: 1566-1571.
6. Matsuzaki K, Udagawa N, Takahashi N, Yamaguchi K, Yasuda H, et al. (1998) Osteoclast differentiation factor (ODF) induces osteoclast-like cell formation in human peripheral blood mononuclear cell cultures. Biochem Biophys Res Commun 246: 199-204.
7. Roodman GD, (2004) Mechanisms of bone metastasis. N Engl J Med 350: 1655-1664.
8. Bhatia P, Sanders MM, Hansen MF, (2005) Expression of receptor activator of nuclear factor kappaB is inversely correlated with metastatic phenotype in breast carcinoma. Clin Cancer Res 11: 162-165.
9. Lai FP, Cole-Sinclair M, Cheng WJ, Quinn JM, Gillespie MT, et al. (2004) Myeloma cells can directly contribute to the pool of RANKL in bone bypassing the classic stromal and osteoblast pathway of osteoclast stimulation. Br J Haematol 126: 192-201.
10. Farrugia AN, Atkins GJ, To LB, Pan B, Horvath N, et al. (2003) Receptor activator of nuclear factor-kappaB ligand expression by human myeloma cells mediates osteoclast formation in vitro and correlates with bone destruction in vivo. Cancer Res 63: 5438-5445.
11. Huang L, Xu J, Wood DJ, Zheng MH, (2000) Gene expression of osteoprotegerin ligand, osteoprotegerin, and receptor activator of NF-kappaB in giant cell tumor of bone: possible involvement in tumor cell-induced osteoclast-like cell formation. Am J Pathol 156 pp. 761-767.
12. Huang L, Cheng YY, Chow LT, Zheng MH, Kumta SM, (2003) Receptor activator of NFkappaB ligand (RANKL) is expressed in chondroblastoma: possible involvement in osteoclastic giant cell recruitment. Mol Pathol 56: 116-120.
13. Granchi D, Amato I, Battistelli L, Avnet S, Capaccioli S, et al. (2004) In vitro blockade of receptor activator of nuclear factor-kappaB ligand prevents osteoclastogenesis induced by neuroblastoma cells. Int J Cancer 111: 829-838.
14. Tada T, Jimi E, Okamoto M, Ozeki S, Okabe K, (2005) Oral squamous cell carcinoma cells induce osteoclast differentiation by suppression of osteoprotegerin expression in osteoblasts. Int J Cancer 116: 253-262.
15. Wittrant Y, Lamoureux F, Mori K, Riet A, Kamijo A, et al. (2006) RANKL directly induces bone morphogenetic protein-2 expression in RANK-expressing POS-1 osteosarcoma cells. Int J Oncol 28: 261-269.
16. Jones DH, Nakashima T, Sanchez OH, Kozieradzki I, Komarova SV, et al. (2006) Regulation of cancer cell migration and bone metastasis by RANKL. Nature 440: 692-696.
17. Cross SS, Harrison RF, Balasubramanian SP, Lippitt JM, Evans CA, et al. (2006) Expression of receptor activator of nuclear factor kappa beta ligand (RANKL) and tumour necrosis factor related, apoptosis inducing ligand (TRAIL) in breast cancer, and their relations with osteoprotegerin, oestrogen receptor, and clinicopathological variables. J Clin Pathol 59: 716-720.
18. Chen G, Sircar K, Aprikian A, Potti A, Goltzman D, et al. (2006) Expression of RANKL/RANK/OPG in primary and metastatic human prostate cancer as markers of disease stage and functional regulation. Cancer 107: 289-298.
19. Brown JM, Zhang J, Keller ET, (2004) Opg, RANKl, and RANK in cancer metastasis: expression and regulation. Cancer Treat Res 118: 149-172.
20. Sasaki A, Ishikawa K, Haraguchi N, Inoue H, Ishio T, et al. (2007) Receptor activator of nuclear factor-kappaB ligand (RANKL) expression hepatocellular carcinoma with bone metastasis. Ann Surg Oncol 14: 1191-1199.
21. Armstrong AP, Miller RE, Jones JC, Zhang J, Keller ET, et al. (2008) RANKL acts directly on RANK-expressing prostate tumor cells and mediates migration and expression of tumor metastasis genes. Prostate 68: 92-104.
22. Mikami S, Katsube K, Oya M, Ishida M, Kosaka T, et al. (2009) Increased RANKL expression is related to tumour migration and metastasis of renal cell carcinomas. J Pathol 218: 530-539.
23. Santini D, Perrone G, Roato I, Godio L, Pantano F, et al. (2011) Expression pattern of receptor activator of NFκB (RANK) in a series of primary solid tumors and related bone metastases. J Cell Physiol 226 (3): 780-784.
24. Van Poznak C, Cross SS, Saggese M, Hudis C, Panageas KS, et al. (2006) Expression of osteoprotegerin (OPG), TNF related apoptosis inducing ligand (TRAIL), and receptor activator of nuclear factor kB ligand (RANKL) in human breast tumours. J Clin Pathol 59: 56-63.
25. Danovi SA, (2010) Hormonally driven. Nat Rev Cancer 10 (7): 45.
26. Joshi PA, Jackson HW, Beristain AG, Di Grappa MA, Mote PA, et al. (2010) Progesterone induces adult mammary stem cell expansion. Nature 465: 803-807.
27. Asselin-Labat ML, Vaillant F, Sheridan JM, Pal B, Wu D, et al. (2010) Control of mammary stem cell function by steroid hormone signaling. Nature 465: 798-802.
28. Beleut M, Rajaram RD, Caikovski M, Ayyanan A, Germano D, et al. (2010) Two distinct mechanisms underlie progesterone-induced proliferation in the mammary gland. Proc Natl Acad Sci U S A 107 (7): 2989-2994.
29. Jones DH, Nakashima T, Sanchez OH, Kozieradzki I, Komarova SV, et al. (2006) Regulation of cancer cell migration and bone metastasis by RANKL. Nature 440: 692-696.
30. Smid M, Wang Y, Klijn JG, Sieuwerts AM, Zhang Y, et al. (2006) Genes associated with breast cancer metastatic to bone. Journal of Clinical Oncology 24: 2261-2267.
31. Kang Y, Siegel PM, Shu W, Drobnjak M, Kakonen SM, et al. (2003) A multigenic program mediating breast cancer metastasis to bone. Cancer Cell 3: 537-549.
32. Wang Y, Klijn JG, Zhang Y, Sieuwerts AM, Look MP, et al. (2005) Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet 365: 671-679.
33. McClung MR, Lewiecki EM, Cohen SB, Bolognese MA, Woodson GC, et al. (2006) Denosumab in postmenopausal women with low bone mineral density. N Engl J Med 354: 821-831.
34. Lipton A, Steger GG, Figueroa J, Alvarado C, Solal-Celigny P, et al. (2007) Randomized active-controlled phase II study of denosumab efficacy and safety in patients with breast cancer-related bone metastases. J Clin Oncol 25: 4431-4437.
35. van de Vijver MJ, He YD, van't Veer LJ, Dai H, Hart AA, et al. (2002) A gene expression signature as a predictor of survival in breast cancer. N Engl J Med 347: 1999-2009.
36. Sørlie T, Perou CM, Tibshirani R, Aas T, Geisler S, et al. (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 98: 10869-10874.
37. Chen G, Sircar K, Aprikian A, Potti A, Goltzman D, et al. (2006) Expression of RANKL/RANK/OPG in primary and metastatic human prostate cancer as markers of disease stage and functional regulation. Cancer 107: 289-298.
38. Pylayeva Y, Gillen KM, Gerald W, Beggs HE, Reichardt LF, et al. (2009) Ras- and PI3K-dependent breast tumorigenesis in mice and humans requires focal adhesion kinase signaling. J Clin Invest 119 (2): 252-266.
39. Kaplan EL, Meier P, (1958) Non parametric estimation from incomplete observations. J Am Stat Assoc 53: 457-481.
40. Cox DR, (1972) Regression models and life tables. J R Stat Soc B 34: 187-220.